Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

Open Menu
Ein Forscher träufelt aus einer kleinen Pipette eine Flüssigkeit in ein Reagenzglas. Mehrere Reagenzgläser und ein Erlenmeyerkolben vorn rechts sind mit einer hellblauen, klaren Flüssigkeit gefüllt. Kopf und Schultern des Forschers sind nur unscharf im Hintergrund zu erkennen.

Working Group Hohendanner

You are here:

Research is conducted with state-of the art methods including confocal and ratiometric Ca2+ imaging with high throughput devices, molecular biology, tissue/whole-heart multi-electrode array measurements etc. The group utilizes in-vivo and in-vitro human setups (e.g. isolated atrial cardiomyocytes from human cardiac tissue), iPS-derived cardiomyocytes and various animal models.

Atrial cardiomyopathy confers high mortality, especially in patients with heart failure.
In-vitro drug screening.

Atrial cardiomyopathy – from bench to bedside

Besides ventricular dysfunction, pathological enlargement of the atria, often accompanied by the occurrence of atrial fibrillation, is a frequently observed characteristic of heart failure. This atrial enlargement is related to what is known as "atrial cardiomyopathy", which is associated with an increased risk of atrial arrhythmias and a deterioration of the mechanical atrial function and thus ventricular filling. Atrial cardiomyopathy is also associated with increased mortality, independently of ventricular function per se. Atrial cardiomyopathy is particularly common in heart failure with reduced ejection fraction (HFrEF) and a hallmark feature of heart failure with preserved ejection fraction (HFpEF). The Hohendanner lab has previously described various relevant mechanisms in HFpEF and HFrEF animal models, but also in atrial cardiomyopathy in humans, and identified potential therapeutic targets. We, for example, only recently provided evidence for combined SGLT1/2 inhibition as a potential preventive drug in atrial fibrillation. Ongoing research addresses the interplay of ventricular and atrial changes (atrioventricular coupling), the presence of atrial cardiomyopathy and the development of atrial fibrillation in heart failure.

Novel tools in precision medicine – targeting arrhythmias

The treatment of atrial and ventricular arrhythmias is still an unmet clinical need. Beyond atrial cardiomyopathy, the Hohendanner lab aims to find new translational approaches to treat cardiac arrhythmias. As an example the group only recently developed a novel iPS-derived cardiomyocyte assay for precision medicine. This tool was used during the COVID-19 pandemic to test pharmacological approaches in severe disease related cardiac dysfunction with imminent translational potential.